Drug Information Association Logo

TRANSLATION OF PERSONALISED MEDICINE CONCEPTS

Track:
Personalised Medicine: Drug-companion diagnostics combinations

Day & Time:
March 26, 9:00AM - 10:30AM (Central European Standard Time)

Session Number:
0501

Room Number:
Room I

Type:
Session

Title:
TRANSLATION OF PERSONALISED MEDICINE CONCEPTS

Chair(s):
Michael Zuehlsdorf
Global Head Translational and Biomarker Research Oncology
Merck Group, Germany

Description:
This session addresses the latest scientific developments driving personalised medicine, adaptive trial concepts supportive of personalized medicine and early scientific advice for the development of personalized medicine from regulators, HTA bodies and payers.

Presentation(s) & Speaker(s):
Latest Scientific Developments/New Biomarker Technologies
Giulio Superti-Furga
CEO and Scientific Director
Research Center for Molecular Medicine of the Austrian Academy of Sciences, Austria

Scientific Advice from Regulators
Jan Regnstrom, MD, PhD
Scientific Administrator, Preauthorization Evaluation of Medicines for Human Use
European Medicines Agency, United Kingdom

Adaptive Enrichment Files
Zoran Antonijevic, MSc
Senior Director, Strategic Consulting
Cytel, Inc., United States